|
Citation
|
Sumukadas D, Price R, McMurdo MET, Rauchhaus P, Struthers A, McSwiggan S, Arnold G, Abboud R, Witham M. Age Ageing 2018; 47(1): 75-81. |
|
Affiliation
|
Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK. |
|
Abstract
|
DESIGN: double-blind, parallel group, placebo-controlled randomised trial.
METHODS: we recruited people aged >65 years with at least one fall in the previous year. Participants received 4 mg perindopril or placebo daily for 15 weeks. The primary outcome was the between-group difference in force-plate measured anteroposterior (AP) sway at 15 weeks. Secondary outcomes included other measures of postural sway, limits of stability during maximal forward, right and left leaning, blood pressure, muscle strength, 6-min walk distance and falls. The primary outcome was assessed using two-way ANOVA, adjusted for baseline factors.
RESULTS: we randomised 80 participants. Mean age was 78.0 (SD 7.4) years; 60 (75%) were female. About 77/80 (96%) completed the trial. At 15 weeks there were no significant between-group differences in AP sway with eyes open (mean difference 0 mm, 95% CI -8 to 7 mm, P = 0.91) or eyes closed (mean difference 2 mm, 95% CI -7 to 12 mm, P = 0.59); no differences in other measures of postural stability, muscle strength or function. About 16/40 (42%) of patients in each group had orthostatic hypotension at follow-up. The median number (IQR) of falls was 1 (0,4) in the perindopril versus 1 (0,2) in the placebo group (P = 0.24).
CONCLUSIONS: perindopril did not improve postural sway in older people at risk of falls. CLINICAL TRIALS REGISTRATION: ISRCTN58995463.
Language: en |